Hypoxia-inducible factor prolyl hydroxylase inhibitor induces functional HIF transcriptional response by stabilizing HIF and inhibiting PHD, and promotes the expression of erythropoietin receptor while promoting the production of endogenous EPO, thereby improving anemia. The gene discussed is EPO; the disease is anemia (phenotype).